Abzena PLC Exercise of options (6355D)

TIDMABZA

RNS Number : 6355D

Abzena PLC

10 October 2018

Abzena plc

Exercise of options

Cambridge, UK, 10 October 2018 - Abzena plc (AIM: ABZA, 'Abzena', the 'Company' or the 'Group') announces that, on 10 October 2018, 672,980 new ordinary shares of GBP0.002 each in the Company ('Ordinary Shares') were issued and allotted following the exercise of share options by employees and former employees. The new Ordinary Shares rank pari passu with the Company's existing issued Ordinary Shares and have been admitted to trading on AIM under the Company's block admission.

Total voting rights

Following the issue of the 672,980 new Ordinary Shares as set out above, the Company's issued share capital comprises 214,893,379 Ordinary Shares with voting rights. No Ordinary Shares are held in treasury. The total number of voting rights in the Company is therefore 214,893,379. This figure of 214,893,379 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
 Director                  New Ordinary     Direct and indirect   % of issued share 
                       Shares resulting    interest in Ordinary          capital(1) 
                  from option exercises               Shares(1) 
 John Burt                      151,673               2,302,238                1.1% 
                -----------------------  ----------------------  ------------------ 
 Julian Smith                    83,253                 608,672                0.3% 
                -----------------------  ----------------------  ------------------ 
 

(1) As enlarged by the issue of 672,980 new Ordinary Shares pursuant to the option exercise.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

   1          Details of the person discharging managerial responsibilities/person closely associate 
 
 1(a)   Name                John Burt 
 1(b)   Position / Status   Chief Executive Officer 
       ------------------  ------------------------ 
 
   2          Reason for the Notification 
 
 2(a)   Reason                 Exercise of Stock Options 
 2(b)   Initial notification   Initial 
         / amendment 
       ---------------------  -------------------------- 
 

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 
 3(a)   Name                      Abzena plc 
 3(b)   Legal Entity Identifier   213800SB5JV4O28JRM14 
         ("LEI") 
       ------------------------  --------------------- 
 

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 
 4(a)    Description of the          Abzena plc ordinary shares of 
          financial instrument,       GBP0.002 each 
          type of instrument 
         Identification code         GB00BN65QN46 
        --------------------------  ------------------------------------- 
 4(b)    Nature of transaction       Exercise of 151,673 stock options 
        --------------------------  ------------------------------------- 
 4(c)    Price(s) and volumes(s)     Price                      Volume 
                                     GBP0.0002                  151,673 
    (exercise price) 
  -----------------------------------------------------------  ---------- 
 4(d)    Aggregated information      Price                      Volume 
                                     GBP0.0002                  151,673 
    (exercise price) 
  -----------------------------------------------------------  ---------- 
 4(e)    Date of transaction         10 October 2018 
        --------------------------  ------------------------------------- 
 4(f)    Place of the transaction    N/a 
        --------------------------  ------------------------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

   1          Details of the person discharging managerial responsibilities/person closely associate 
 
 1(a)   Name                Julian Smith 
 1(b)   Position / Status   Director 
       ------------------  ------------- 
 
   2          Reason for the Notification 
 
 2(a)   Reason                 Exercise of Stock Options 
 2(b)   Initial notification   Initial 
         / amendment 
       ---------------------  -------------------------- 
 

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 
 3(a)   Name                      Abzena plc 
 3(b)   Legal Entity Identifier   213800SB5JV4O28JRM14 
         ("LEI") 
       ------------------------  --------------------- 
 

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 
 4(a)    Description of the          Abzena plc ordinary shares of 
          financial instrument,       GBP0.002 each 
          type of instrument 
         Identification code         GB00BN65QN46 
        --------------------------  ------------------------------------ 
 4(b)    Nature of transaction       Exercise of 83,253 stock options 
        --------------------------  ------------------------------------ 
 4(c)    Price(s) and volumes(s)     Price                      Volume 
                                     GBP0.0002                  83,253 
    (exercise price) 
  -----------------------------------------------------------  --------- 
 4(d)    Aggregated information      Price                      Volume 
                                     GBP0.0002                  83,253 
    (exercise price) 
  -----------------------------------------------------------  --------- 
 4(e)    Date of transaction         10 October 2018 
        --------------------------  ------------------------------------ 
 4(f)    Place of the transaction    N/a 
        --------------------------  ------------------------------------ 
 

-Ends-

Enquiries:

 
Abzena plc 
 John Burt, Chief Executive Officer               [phone] 
N+1 Singer (Nomad & Broker) 
 Aubrey Powell / Ben Farrow                       [phone] 
Instinctif Partners                               [phone] 
 Melanie Toyne Sewell / Rozi Morris / Alex Shaw    [e-mail] 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --      Proprietary site-specific conjugation technologies and novel payloads for ADC development; 
   --      GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and 
   --      GMP analytical services for biopharmaceutical manufacturing projects. 

For more information, please see www.abzena.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEADEEFDXPFFF

(END) Dow Jones Newswires

October 10, 2018 09:40 ET (13:40 GMT)